Spero Therapeutics, Inc. Stock-Based Compensation
Spero Therapeutics, Inc. (SPRO) reported Stock-Based Compensation of $822.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-12
- Spero Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $822.00K, a 15.13% increase year-over-year.
- Spero Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.11M, a 28.41% decline year-over-year.
- Spero Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.01M, a 33.00% decline year-over-year.
- Spero Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.05M, a 51.35% decline year-over-year.
- Spero Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $4.33M, a 44.50% decline from fiscal 2024.
- Spero Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $7.79M, a 1.75% decline from fiscal 2023.
- Spero Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $7.93M, a 13.05% decline from fiscal 2022.
- Spero Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $9.12M, a 3.26% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $822.00K 10-Q · filed 2026-08-12 | $1.94M 10-Q · filed 2026-08-12 | $2.94M derived: sum of 3 quarters · filed 2026-08-12 | $3.99M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.11M 10-Q · filed 2026-05-13 | $2.12M derived: sum of 2 quarters · filed 2026-05-13 | $3.17M derived: sum of 3 quarters · filed 2026-05-13 | $3.88M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $2.06M derived: sum of 2 quarters · filed 2026-03-26 | $2.77M derived: sum of 3 quarters · filed 2026-08-12 | $4.33M 10-K · filed 2026-03-26 |
| 2025-09-30 | $1.05M 10-Q · filed 2025-11-13 | $1.76M derived: sum of 2 quarters · filed 2026-08-12 | $3.32M 10-Q · filed 2025-11-13 | $4.82M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $714.00K 10-Q · filed 2026-08-12 | $2.27M 10-Q · filed 2026-08-12 | $3.77M derived: sum of 3 quarters · filed 2026-08-12 | $5.93M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $1.56M 10-Q · filed 2026-05-13 | $3.06M derived: sum of 2 quarters · filed 2026-05-13 | $5.21M derived: sum of 3 quarters · filed 2026-05-13 | $7.33M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $3.66M derived: sum of 2 quarters · filed 2026-03-26 | $5.77M derived: sum of 3 quarters · filed 2026-03-26 | $7.79M 10-K · filed 2026-03-26 |
| 2024-09-30 | $2.15M 10-Q · filed 2025-11-13 | $4.27M derived: sum of 2 quarters · filed 2025-11-13 | $6.29M 10-Q · filed 2025-11-13 | $8.29M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $2.11M 10-Q · filed 2025-08-12 | $4.14M 10-Q · filed 2025-08-12 | $6.13M derived: sum of 3 quarters · filed 2025-08-12 | $8.04M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $2.02M 10-Q · filed 2025-05-13 | $4.02M derived: sum of 2 quarters · filed 2025-05-13 | $5.93M derived: sum of 3 quarters · filed 2025-05-13 | $7.79M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $3.90M derived: sum of 2 quarters · filed 2025-03-27 | $5.76M derived: sum of 3 quarters · filed 2025-03-27 | $7.93M 10-K · filed 2025-03-27 |
| 2023-09-30 | $1.91M 10-Q · filed 2024-11-14 | $3.77M derived: sum of 2 quarters · filed 2024-11-14 | $5.93M 10-Q · filed 2024-11-14 | $8.43M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $1.86M 10-Q · filed 2024-08-05 | $4.03M 10-Q · filed 2024-08-05 | $6.52M derived: sum of 3 quarters · filed 2024-08-05 | $8.63M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | $2.17M 10-Q · filed 2024-05-15 | $4.67M derived: sum of 2 quarters · filed 2024-05-15 | $6.77M derived: sum of 3 quarters · filed 2024-05-15 | $8.09M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $4.60M derived: sum of 2 quarters · filed 2024-03-13 | $5.92M derived: sum of 3 quarters · filed 2024-03-13 | $9.12M 10-K · filed 2024-03-13 |
| 2022-09-30 | $2.11M 10-Q · filed 2023-11-13 | $3.42M derived: sum of 2 quarters · filed 2023-11-13 | $6.63M 10-Q · filed 2023-11-13 | $9.55M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $1.32M 10-Q · filed 2023-08-10 | $4.52M 10-Q · filed 2023-08-10 | $7.45M derived: sum of 3 quarters · filed 2023-08-10 | $9.78M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $3.20M 10-Q · filed 2023-05-11 | $6.13M derived: sum of 2 quarters · filed 2023-05-11 | $8.46M derived: sum of 3 quarters · filed 2023-05-11 | $10.62M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $2.93M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $5.26M derived: sum of 2 quarters · filed 2023-03-30 | $7.42M derived: sum of 3 quarters · filed 2023-03-30 | $9.43M 10-K · filed 2023-03-30 |
| 2021-09-30 | $2.33M 10-Q · filed 2022-11-14 | $4.49M derived: sum of 2 quarters · filed 2022-11-14 | $6.50M 10-Q · filed 2022-11-14 | $7.87M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $2.16M 10-Q · filed 2022-08-10 | $4.17M 10-Q · filed 2022-08-10 | $5.54M derived: sum of 3 quarters · filed 2022-08-10 | $6.74M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $2.01M 10-Q · filed 2022-05-16 | $3.37M derived: sum of 2 quarters · filed 2022-05-16 | $4.57M derived: sum of 3 quarters · filed 2022-05-16 | $5.79M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $2.56M derived: sum of 2 quarters · filed 2022-03-31 | $3.78M derived: sum of 3 quarters · filed 2022-03-31 | $4.89M 10-K · filed 2022-03-31 |
| 2020-09-30 | $1.20M 10-Q · filed 2021-11-10 | $2.41M derived: sum of 2 quarters · filed 2021-11-10 | $3.52M 10-Q · filed 2021-11-10 | $4.45M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $1.21M 10-Q · filed 2021-08-05 | $2.32M 10-Q · filed 2021-08-05 | $3.25M derived: sum of 3 quarters · filed 2021-08-05 | $4.23M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $1.11M 10-Q · filed 2021-05-06 | $2.04M derived: sum of 2 quarters · filed 2021-05-06 | $3.02M derived: sum of 3 quarters · filed 2021-05-06 | $3.95M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $929.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $1.91M derived: sum of 2 quarters · filed 2021-03-11 | $2.84M derived: sum of 3 quarters · filed 2021-03-11 | $3.78M 10-K · filed 2021-03-11 |
| 2019-09-30 | $981.00K 10-Q · filed 2020-11-05 | $1.91M derived: sum of 2 quarters · filed 2020-11-05 | $2.85M 10-Q · filed 2020-11-05 | $3.62M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $933.00K 10-Q · filed 2020-08-06 | $1.87M 10-Q · filed 2020-08-06 | $2.63M derived: sum of 3 quarters · filed 2020-08-06 | $3.34M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $933.00K 10-Q · filed 2020-05-08 | $1.70M derived: sum of 2 quarters · filed 2020-05-08 | $2.41M derived: sum of 3 quarters · filed 2020-05-08 | $3.07M derived: sum of 4 quarters · filed 2020-05-08 |
| 2018-12-31 | $769.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $1.47M derived: sum of 2 quarters · filed 2020-03-16 | $2.13M derived: sum of 3 quarters · filed 2020-03-16 | $2.75M 10-K · filed 2020-03-16 |
| 2018-09-30 | $705.00K 10-Q · filed 2019-11-04 | $1.37M derived: sum of 2 quarters · filed 2019-11-04 | $1.98M 10-Q · filed 2019-11-04 | $2.35M derived: sum of 4 quarters · filed 2019-11-04 |
| 2018-06-30 | $661.00K 10-Q · filed 2019-08-08 | $1.27M 10-Q · filed 2019-08-08 | $1.65M derived: sum of 3 quarters · filed 2019-08-08 | $2.58M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $614.00K 10-Q · filed 2019-05-09 | $987.00K derived: sum of 2 quarters · filed 2019-05-09 | $1.92M derived: sum of 3 quarters · filed 2019-05-09 | $1.98M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $373.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $1.30M derived: sum of 2 quarters · filed 2019-03-14 | $1.36M derived: sum of 3 quarters · filed 2019-03-14 | $1.43M 10-K · filed 2019-03-14 |
| 2017-09-30 | $931.00K 10-Q · filed 2018-11-08 | $992.00K derived: sum of 2 quarters · filed 2018-11-08 | $1.05M 10-Q · filed 2018-11-08 | $1.12M derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-06-30 | $61.00K 10-Q · filed 2018-08-09 | $123.00K 10-Q · filed 2018-08-09 | $186.00K derived: sum of 3 quarters · filed 2019-03-14 | $246.00K derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-03-31 | $62.00K 10-Q · filed 2018-05-10 | $125.00K derived: sum of 2 quarters · filed 2019-03-14 | $185.00K derived: sum of 3 quarters · filed 2019-03-14 | |
| 2016-12-31 | $63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $123.00K derived: sum of 2 quarters · filed 2019-03-14 | $180.00K 10-K · filed 2019-03-14 | |
| 2016-09-30 | $60.00K 10-Q · filed 2017-12-14 | $117.00K 10-Q · filed 2017-12-14 | ||
| 2015-12-31 | $21.00K 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |